---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021650"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:21:01.492929+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MindMed reports FY2023 net loss $95.7M; Phase2b MM120 shows 7.6-point HAM-A reduction for GAD

## Summary
- Cash and equivalents $99.7M vs $142.1M at Dec 2022; expected to fund operations into 2026.
- Net loss $95.7M vs $56.8M in 2022; R&D expenses $52.1M (up $15.9M) driven by MM120 Phase 2b trial.
- Phase 2b MM120 (100 µg) achieved 7.6-point HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response rate.
- Plans End-of-Phase 2 FDA meeting H1 2024, Phase 3 MM120 GAD program start H2 2024; March 7 investor event for 12-week data.
- Initiated Phase 1 trial of MM402 (R(-)-MDMA) for ASD in Q4 2023.

## SEC filing metadata
- accession: 0000950170-24-021650
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017024021650/0000950170-24-021650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017024021650/mnmd-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021650
- JSON: https://secwatch.observer/filing/0000950170-24-021650.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021650.txt

## Key facts
- Earnings Releases
  Definium Therapeutics, Inc. reported financial results for year ended December 31, 2023.
  - Period: year ended December 31, 2023
  - Result: reported results
  source text: MindMed Reports 2023 Financial Results and Business Updates --Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024-- --Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD)-- --Conference call to discuss year-end financial results at 8:00 a.m. EST--
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017024021650/0000950170-24-021650-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.